Malignancies occurring during the follow-up of the study patients and controls
| . | Patients (n = 737) . | Controls (n = 1438) . |
|---|---|---|
| Genito-urinary | 8 (1.0) | 16 (1.1) |
| Gastrointestinal and digestive | 5 (0.7) | 14 (0.9) |
| Skin* | 5 (0.7) | 4 (0.3) |
| Respiratory tract | 3 (0.4) | 8 (0.6) |
| Breast | 3 (0.4) | 7 (0.5) |
| Hematological malignancies | 2 (0.3) | 5 (0.3) |
| Brain | 2 (0.1) | |
| Total | 26 (3.5) | 56 (3.9) |
| . | Patients (n = 737) . | Controls (n = 1438) . |
|---|---|---|
| Genito-urinary | 8 (1.0) | 16 (1.1) |
| Gastrointestinal and digestive | 5 (0.7) | 14 (0.9) |
| Skin* | 5 (0.7) | 4 (0.3) |
| Respiratory tract | 3 (0.4) | 8 (0.6) |
| Breast | 3 (0.4) | 7 (0.5) |
| Hematological malignancies | 2 (0.3) | 5 (0.3) |
| Brain | 2 (0.1) | |
| Total | 26 (3.5) | 56 (3.9) |
Numbers in parentheses indicate percentages.
Including basal cell carcinoma.